Optimizing clinical drug product performance: applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid

Research output: Contribution to journalJournal articleResearchpeer-review

  • Paul A. Dickinson
  • Filippos Kesisoglou
  • Talia Flanagan
  • Marilyn N. Martinez
  • Hitesh B. Mistry
  • John R. Crison
  • James E. Polli
  • Maria T. Cruañes
  • Abu T. M. Serajuddin
  • Müllertz, Anette
  • Jack A. Cook
  • Arzu Selen

The aim of Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid is to facilitate optimization of clinical performance of drug products. BioRAM strategy relies on therapy-driven drug delivery and follows an integrated systems approach for formulating and addressing critical questions and decision-making (J Pharm Sci. 2014,103(11): 3777-97). In BioRAM, risk is defined as not achieving the intended in vivo drug product performance, and success is assessed by time to decision-making and action. Emphasis on time to decision-making and time to action highlights the value of well-formulated critical questions and well-designed and conducted integrated studies. This commentary describes and illustrates application of the BioRAM Scoring Grid, a companion to the BioRAM strategy, which guides implementation of such an integrated strategy encompassing 12 critical areas and 6 assessment stages. Application of the BioRAM Scoring Grid is illustrated using published literature. Organizational considerations for implementing BioRAM strategy, including the interactions, function, and skillsets of the BioRAM group members, are also reviewed. As a creative and innovative systems approach, we believe that BioRAM is going to have a broad-reaching impact, influencing drug development and leading to unique collaborations influencing how we learn, and leverage and share knowledge.

Original languageEnglish
JournalJournal of Pharmaceutical Sciences
Issue number11
Pages (from-to)3243-3255
Number of pages13
Publication statusPublished - Nov 2016

ID: 168936391